<DOC>
	<DOC>NCT00300950</DOC>
	<brief_summary>The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.</brief_summary>
	<brief_title>Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>(A few general items required) Patients with nonmetastatic pancreas cancer postresection that have a productrelated ras mutation &gt;18 years of age Negative skin test for hypersensitivity to Saccharomyces cerevisiae Metastatic pancreas cancer patients postresection Patients with no productrelated ras mutation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pancreas Cancer</keyword>
	<keyword>resected pancreas cancer</keyword>
	<keyword>non-metastatic pancreas cancer</keyword>
</DOC>